Sarcoma News

A CDK9 inhibitor, known as KB-0742, showed preliminary evidence of clinical activity in patients with various sarcomas, according to a study presented at the Connective Tissue Oncology Society Annual Meeting.

Sandra D’Angelo, MD, talked about preliminary results from a phase 1 study of FHD-609, a bromodomain-containing protein 9 degrader, in patients with advanced synovial sarcoma or SMARCB1-loss tumors in a video interview with Healio.

Vimseltinib improved objective response rate compared with placebo for patients with tenosynovial giant cell tumor, according to topline data from the agent’s manufacturer.

The National Academy of Medicine announced the election of 90 regular members and 10 international members.

ASCO released a research statement outlining new recommendations regarding the appropriate assessment of ovarian toxicity in cancer clinical trials.

The FDA announced several regulatory actions the past few weeks.

Atezolizumab induced durable responses among more than one-third of patients with advanced alveolar soft part sarcoma, according to data published in The New England Journal of Medicine.

Damon Reed, MD, has been appointed inaugural head of the division of pediatric solid tumors at Memorial Sloan Kettering Cancer Center.

The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country.

The FDA announced several regulatory actions the past few weeks.